MENU
+Compare
COLL
Stock ticker: NASDAQ
AS OF
Sep 26, 03:01 PM (EDT)
Price
$34.49
Change
-$0.16 (-0.46%)
Capitalization
1.09B

COLL stock forecast, quote, news & analysis

Collegium Pharmaceutical Inc is a specialty pharmaceutical company... Show more

COLL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. COLL showed earnings on August 07, 2025. You can read more about the earnings report here.
Interact to see
Advertisement
A.I.Advisor
a Summary for COLL with price predictions
Sep 25, 2025

COLL's Stochastic Oscillator remains in oversold zone for 8 days

The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where COLL advanced for three days, in of 304 cases, the price rose further within the following month. The odds of a continued upward trend are .

COLL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The 10-day RSI Indicator for COLL moved out of overbought territory on September 04, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 41 similar instances where the indicator moved out of overbought territory. In of the 41 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on September 12, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on COLL as a result. In of 101 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for COLL turned negative on August 29, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 39 similar instances when the indicator turned negative. In of the 39 cases the stock turned lower in the days that followed. This puts the odds of success at .

COLL moved below its 50-day moving average on September 23, 2025 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where COLL declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for COLL entered a downward trend on September 25, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock slightly better than average.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. COLL’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.701) is normal, around the industry mean (16.880). P/E Ratio (32.689) is within average values for comparable stocks, (73.296). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.947). COLL has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.030). P/S Ratio (1.951) is also within normal values, averaging (45.617).

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are ZOETIS (NYSE:ZTS), Teva Pharmaceutical Industries Limited (NYSE:TEVA), Elanco Animal Health (NYSE:ELAN), Bausch Health Companies (NYSE:BHC), BioCryst Pharmaceuticals (NASDAQ:BCRX), Avadel Pharmaceuticals plc (NASDAQ:AVDL), Tilray Brands (NASDAQ:TLRY), Canopy Growth Corp (NASDAQ:CGC), Aurora Cannabis (NASDAQ:ACB), Journey Medical Corp (NASDAQ:DERM).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 3.85B. The market cap for tickers in the group ranges from 5.57K to 63.66B. AGN holds the highest valuation in this group at 63.66B. The lowest valued company is BGPPF at 5.57K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was -1%. For the same Industry, the average monthly price growth was 25%, and the average quarterly price growth was 68%. RGTLF experienced the highest price growth at 991%, while ZYBT experienced the biggest fall at -68%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was -16%. For the same stocks of the Industry, the average monthly volume growth was -74% and the average quarterly volume growth was 59%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 52
P/E Growth Rating: 65
Price Growth Rating: 54
SMR Rating: 83
Profit Risk Rating: 90
Seasonality Score: -22 (-100 ... +100)
View a ticker or compare two or three
COLL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a developer of pharmaceutical products

Industry PharmaceuticalsGeneric

Profile
Fundamentals
Details
Industry
Pharmaceuticals Other
Address
100 Technology Center Drive
Phone
+1 781 713-3699
Employees
197
Web
https://www.collegiumpharma.com